Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02031458
Title A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - BIRCH
Acronym BIRCH
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications
Therapies
Age Groups: adult
Covered Countries USA | TUR | SVN | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BGR | BEL | AUS


No variant requirements are available.